Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy

Biochemical Pharmacology

Volumn 52, Issue 3, 1996, Pages 455-463

  Houba, Pieter H J ^b   Leenders, Ruben G G ^b   Boven, Epie ^b   Scheeren, Johannes W ^b   Pinedo, Herbert M ^b   Haisma, Hidde J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

ADEPT; anthracycline glucuronide prodrugs; daunorubicin; human glucuronidase

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBODY; BETA GLUCURONIDASE; DAUNORUBICIN; DAUNORUBICIN GLUCURONIDE; DOXORUBICIN; EPIRUBICIN; EPIRUBICIN GLUCURONIDE; NEW DRUG; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROPHILICITY; LIPOPHILICITY; METABOLIC ACTIVATION; MOUSE; OVARY CANCER; PH; PRIORITY JOURNAL; SERUM;

EID: 0001144402     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00248-1     Document Type: Article

References (16)

1. 1. Deonarian MP and Epenetos AA, Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer 70: 786-794, 1994.
2. 2. Dutton GJ, Glucuronic Acid, Free and Combined. Academic Press: New York, London, 1966.
3. 3. Fishman WH, Metabolic conjugation and metabolic hydrolysis. Academic Press: New York, London, 1970.
4. 4. Leenders RGG, Gerrits KAA, Ruijtenbeek R, Scheeren HW, Haisma HJ and Boven E, β-Glucuronyl carbamate based promoieties designed for prodrugs in ADEPT. Tetrahedron Lett 36: 1701-1704, 1995.
5. 5. Haisma HJ, Boven E, Van Muijen M, De Jong J, Van der Vijgh WJF and Pinedo HM, A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 66: 474-478, 1992b.
6. 6. Bosslet K, Czech J and Hoffmann D, Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 54: 2151-2159, 1994.
7. 7. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR and Ozols RF, Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 44: 5286-5290, 1984.
8. 8. Watanabe H, Grubb JH and Sly WS, The overexpressed human 46-kDa mannose-6-phosphate receptor mediates endocytosis and sorting of β-glucuronidase. Proc Natl Acad Sci USA 87: 8036-8040, 1990.
9. 9. De Jong J, Guerand WS, Schoofs PR, Bast A and Van der Vijgh WJF, Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection. J Chromatography 570: 209-216, 1991.
10. 10. Martin GR and Jain RK, Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 54: 5670-5674, 1994.
11. 11. Eisenthal R, Cornish-Bowden A, A new graphical procedure for estimating enzyme kinetic parameters. Biochem J 139: 715-720, 1974.
12. 12. Eksborg S, Ehrrsson H and Ekqvist B, Protein binding of anthraquinone glycosides, with special reference to adriamycin. Cancer Chemother Pharmacol 10: 7-10, 1982.
13. 13. Sharma SK, Bagshawe KD, Melton RG and Sherwood RF, Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 21: 109-120, 1992.
14. 14. Haisma HJ, Boven E, Van Muijen M, De Vries R and Pinedo HM, Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol Immunother 34, 343-348, 1992.
15. 15. Mross K, Van der Vijgh WJF, Gall H, Boven E, and Pinedo HM, Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6: 517-526, 1988.
16. 16. Yuan F, Baxter L and Jain RK, Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 51: 3119-3130, 1991.